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Abstract
Purpose To compare qualitative and semi-quantitative PET/CT criteria, and the impact of nodule size on the diagnosis of solitary
pulmonary nodules in a prospective multicentre trial.
Methods Patients with an SPN onCT ≥ 8 and ≤ 30mmwere recruited to the SPUTNIK trial at 16 sites accredited by the UK PET
Core Lab. Qualitative assessment used a five-point ordinal PET-grade compared to the mediastinal blood pool, and a combined
PET/CT grade using the CT features. Semi-quantitative measures included SUVmax of the nodule, and as an uptake ratio to the
mediastinal blood pool (SURBLOOD) or liver (SURLIVER). The endpoints were diagnosis of lung cancer via biopsy/histology or
completion of 2-year follow-up. Impact of nodule size was analysed by comparison between nodule size tertiles.
Results Three hundred fifty-five participants completed PET/CT and 2-year follow-up, with 59% (209/355) malignant nodules.
The AUCs of the three techniques were SUVmax 0.87 (95% CI 0.83;0.91); SURBLOOD 0.87 (95% CI 0.83; 0.91, p = 0.30 versus
SUVmax); and SURLIVER 0.87 (95% CI 0.83; 0.91, p = 0.09 vs. SUVmax). The AUCs for all techniques remained stable across
size tertiles (p > 0.1 for difference), although the optimal diagnostic threshold varied by size. For nodules < 12 mm, an SUVmax
of 1.75 or visual uptake equal to the mediastinum yielded the highest accuracy. For nodules > 16mm, an SUVmax ≥ 3.6 or visual
PET uptake greater than the mediastinum was the most accurate.
Conclusion In this multicentre trial, SUVmax was the most accurate technique for the diagnosis of solitary pulmonary nodules.
Diagnostic thresholds should be altered according to nodule size.
Trial registration ISRCTN - ISRCTN30784948. ClinicalTrials.gov - NCT02013063
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Introduction
Solitary pulmonary nodules, defined as distinct focal pulmo-
nary lesions ≤ 30 mm, are a relatively common finding on
chest CT and present a significant opportunity to improve
patient outcomes as early diagnosis of lung cancer results in
excellent survival rates following surgical resection [1].
However, not all SPNs are due to lung cancer with rates of
malignancy ranging from 3% in screening detected nodules to
60% in clinically detected nodules [2–5]. The accurate char-
acterisation of SPNs is an on-going diagnostic challenge with
significant associated health costs [6].
The probability of malignancy of a nodule is strongly re-
lated to its size, ranging from 6% in nodules 5–10 mm to 64%
in nodules greater than 20 mm in size [7]. As a result, down-
stream work-up of a nodule is dependent on its size with
nodules < 8mms requiring CT follow-up, and nodules 8–
30 mm requiring further work-up with biopsy or PET/CT
[8]. 18Fluorine fluorodeoxyglucose positron emission
tomography/computed tomography (PET/CT) has a high ac-
curacy for the diagnosis of malignancy in nodules with a re-
cent meta-analysis reporting a sensitivity of 89% and a spec-
ificity of 70% [5]. All the studies included in this meta-
analysis used SUVmax cutoffs to determine malignancy sta-
tus. However, SUV is a relative measure of FDG uptake,
which is prone to variability as a result of scanner features,
patient factors, imaging protocols and reconstruction algo-
rithms [9]. Due to this limitation, several authors have sug-
gested the use of a visual ordinal scale comparing the nodule
uptake to that of the mediastinal blood pool [10]. Normalising
the tumour SUVmax to background tissue such as the blood
pool or liver to create a standardised uptake ratio (SUR) can
significantly improve the variability in quantification of tu-
mour uptake and may overcome some of the inherent limita-
tions of isolated tumoral SUVmax measurement [11]. This in
turn may allow for a more nuanced approach to nodule assess-
ment and follow-up through the use of a semi-quantitative
metric rather than allowed for within the visual ordinal
system.
The purpose of the current study was to compare the diag-
nostic accuracy of qualitative and semi-quantitative metrics of
PET/CT in pulmonary nodules in a prospective, multicentre
multivendor environment.
Methods
This is a pre-specified secondary analysis of the SPUTNIK
(Accuracy and Cost-Effectiveness of Dynamic Contrast
Enhanced Computed Tomography in the Characterisation of
Solitary Pulmonary Nodules) trial. This prospective
multicentre observational study compared the diagnostic ac-
curacy of PET/CT with that of dynamic contrast enhanced CT
in a cohort of patients with an indeterminate solitary pulmo-
nary nodule (SPN) (Trial registration: ISRCTN -
ISRCTN30784948; ClinicalTrials.gov - NCT02013063).
The full trial protocol has been previously published [12].
The SPUtNIk Trial was approved by the South West
Research Ethics Committee Centre (UK). All participants pro-
vided written informed consent.
Settings and participants
Participants were recruited from secondary or tertiary outpa-
tient settings at 16 hospitals within the UK.
The inclusion criteria were as follows: soft tissue solitary
indeterminate pulmonary nodule of ≥ 8 mm and ≤ 30 mm on
axial plane measured on lung window using conventional CT
scan with no evidence strongly indicative of malignancy (such
as metastases or local invasion).
Exclusion criteria were as follows: pregnancy; history of
malignancy within the past 2 years; confirmed aetiology of the
nodule at the time of qualifying CT scan; biopsy of nodule
prior to the PET/CT; contra-indication to potential radiother-
apy or surgery; contraindication to scans (assessed by local
procedures).
PET/CT acquisition
The PET/CT examinations were performed on 25 scanners at
the 16 participating centres. Patients were fasted for 6 h (4 h
for diabetics) before receiving the injection of 18F-FDG, with
instructions to avoid strenuous exercise for 6 h before the
scan. Blood glucose levels were checked to ensure they were
less than 11 mmol/l prior to injection. A low-dose CT without
contrast was acquired before the PET acquisition for attenua-
tion correction of the PET images. The injected dose of 18F-
FDG is dependent on the PET system used and the patient
weight according to local protocols. Whole-body imaging be-
gan at 60 ± 10 min (mean ± SD) after injection and was ac-
quired from the skull base to the level of the mid-thigh and
reconstructed using attenuation correction.
All scanners underwent baseline accreditation and annual
quality assurance testing by the UK PET Core Lab [13]. In
addition, the UK PET core lab performed technical checks and
image quality review of all studies.
PET/CT analysis
All PET/CT examinations were reported by local trained phy-
sicians prior to biopsy using visual grading and SUVmax of
the nodule. For this substudy, all images were re-read by a
central lab blinded to the clinical details and nodule status by a
single reader (JRWM) using a dedicated PET/CT reporting
platform (ADW 4.4, GE) using attenuation corrected images.
For the qualitative analysis, the CT and PET images were
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graded. The CT features were graded as follows: 0 = round,
well-defined lesion with laminated or popcorn calcification;
1 = inflammatory features, e.g., air bronchograms, enfolded
lung; 2 = smooth well-defined margins, uniform density; 3 =
lobulated, spiculated or irregular margins; 4 = evidence of me-
tastases. The PET features were graded as follows: 0 = no
visible uptake; 1 = uptake less than mediastinal blood pool;
2 = uptake comparable to mediastinal blood pool; 3 = uptake
greater than mediastinal blood pool; 4 = evidence of distant
metastases (i.e., M1 disease). For the semi-quantitative analy-
sis, the SUVmax and mean of the nodule were measured, as
were the SUVmax andmean of the ascending aorta at the level
of the arch, and within the right lobe of the liver. SUV ratios
(SUR) were calculated between the nodule SUVmax, and the
mediastinal blood pool (SURBLOOD) and liver (SURLIVER).
Pre-specified criteria for malignancy for each of the metrics
were as follows:
– Semi-quantitative: SUVmax ≥ 2.5; SURBLOOD ≥ 1.56;
SURLIVER ≥ 1.12 [14]
– Qualitative: PET grade ≥ 3;
– Combined PET/CT: Grade 4 on PET or CT, Grade 3 on
PET and ≥Grade 2 on CT, or Grade 2 on PET and ≥
Grade 3 on CT [15, 16]
Further exploratory analyses were also performed using
optimised thresholds from the ROC curves derived in the cur-
rent study.
Reference standard
For the diagnostic accuracy, the reference standard was his-
tology or completion of 2 years of nodule surveillance. For a
nodule to be diagnosed as malignant, histological confirma-
tion was required or an increase in nodule size with a specialist
thoracic oncology multi-disciplinary team (MDT) consensus
of certainty of malignancy where biopsy/resection was not
possible. Benign status could be established through either
histology, or through demonstration of stability over 2 years
of CT monitoring.
Statistical analysis
Continuous data is presented as mean ± SD, while ordinal data
is provided as N (%). We considered the diagnostic accuracy
of qualitative and semi-quantitative PET/CT in relation to a
diagnosis of lung cancer by 2 years. The diagnostic accuracy
of the tests was assessed by sensitivity, specificity, positive
predictive value negative predictive value and overall accura-
cy for the pre-specified end points with results for each of
these reported with 95% CIs. Further exploratory analysis
was performed comparing the qualitative PET grading, PET/
CT grading, SUVmax and SURs. Receiver operator
characteristics curves were constructed for this exploratory
analysis to compare accuracy between the techniques. The
overall discriminatory ability was summarised as the area un-
der the roc curve (AUROC) with 95% confidence interval
calculated with 2000 stratified bootstrap replicates.
Optimised cut-points were then derived from these ROC
curves using the Youdin index. Comparison between the
AUROCs was performed using DeLongs test for two corre-
lated ROC curves in pROC. To determine the impact of size
on diagnostic accuracy, the population was split into tertiles
(< 12 mm, 12–16 mm, and > 16 mm), with pairwise compar-
ison of the AUC of the largest nodules with each of the smaller
tertiles. To compare the effects of nodule location, we com-
pared nodules in the right and left lower lobes with those in the
right and left upper lobes, lingula and right middle lobe. For
inter-reader measurement variability assessment between the
site and core reads, a one-way random effects model intraclass
correlation coefficient was calculated for continuous vari-
ables, with Bland-Altman plots also constructed. A square
weighted Cohen Kappa was used for ordinal variables and
an unweighted Cohen Kappa was calculated for the dichoto-
mous cut points of the qualitative and semi-quantitative PET
metrics. P < 0.05 was considered statistically significant.
Analysis was performed using RStudio (Version 1.1.463,
RStudio, Inc.) using the pROC and psych packages [17].
Results
Of the 380 participants recruited, 360 completed their PET/CT
examinations, with 355 (67.9 ± 9.0 years old, 48% female)
completing 2-year follow-up (Fig. 1). Table 1 details the base-
line characteristics of the study participants, and the CT find-
ings of their nodule at baseline leading to their recruitment.
Fifty-five percent reported as being ex-smokers, with 25%
reporting to still be smoking. On the recruitment CT, the nod-
ules were 15.8 ± 5.5 mm on average in diameter (range 8-
30 mm), with the majority (241/355, 68%) being described
as spiculate (CT grade 3). Of the 355 nodules with 2-year
follow-up, 209/355 were malignant (59%).
On PET/CT, malignant nodules were significantly more
likely to be spiculate, and have elevated nodule tracer
uptake—both absolute and relative to the blood and liver
(p < 0.001 for all—see Table 2). Of the semi-quantitative
markers, SUVmax, SURBLOOD and SURLIVER all demonstrat-
ed equivalent diagnostic performance (see Fig. 2). The AUCs
of the three techniques were as follows: SUVmax 0.87 (95%
CI 0.83;0.91); SURBLOOD 0.87 (95% CI 0.83;0.91, p = 0.30
versus SUVmax); SURLIVER 0.87 (95% CI 0.83;0.90, p =
0.09 vs. SUVmax). Considering the techniques as continuous
variables, SUVmax, but not SURBLOOD or SURLIVER, per-
formed significantly better than visual PET-grade (AUC
0.84, 95% CI 0.80; 0.88, p = 0.02 vs SUVmax, p = 0.06 vs
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SURBLOOD, and p = 0.10 vs SURLIVER). However, when
using single-threshold cut-points, a PET uptake of grade 3
showed a similar diagnostic capability to SUVmax≥ 2.5, with
a sensitivity/specificity/accuracy of 77.5%/83.6%/80.0% for
PET grade and 75.6%/84.2%/79.2% for SUVmax. Both
SUR techniques showed similar specificity but poorer sensi-
tivity. In the exploratory analysis, the optimum cut-point
shifted in all techniques to a lower threshold with an improve-
ment in sensitivity and a fall in specificity, with new cut points
in PET grade of ≥ 2, SUVmax≥ 2.05, SURBLOOD ≥ 1.26 and
SURLIVER ≥ 0.96. Again, even with these shifted values, PET
grade and SUVmax showed similar diagnostic capability.
Table 3 details the full sensitivities, specificities, PPV, NPV
and accuracies with 95% CIs for both the pre-specified and
exploratory analysis.
The pre-specified, combined PET/CT grading provided
higher accuracy than the visual grading or the SUVmax pre-
specified criteria and provided an equal diagnostic accuracy to
the optimised cut points of the exploratory analysis for PET
visual and quantitative grading alone (Table 3).
As the size of the nodules increased, so too did the
SUVmax in both the benign and malignant nodules (see
Fig. 3). The size of the nodule had no significant impact on
the overall diagnostic accuracy of PET-CT with the AUCs for
SUVmax, SURBLOOD, PET grade and PET/CT grade not
significantly different for nodules < 12 mm, 12–16 mm or >
16 mm in diameter (p > 0.1 for all size group comparisons).
However, as the size reduced, there was a fall in sensitivity
balanced out by a rise in specificity. This could be
counteracted through a shift in the diagnostic threshold for
each of the nodules sizes for all three techniques, such that
for SUVmax, the optimal cut-point was 1.75 for nodules <
12 mm, 2.55 for nodules 12-16 mm and 3.6 for nodules >
16 mm (see Table 4, and Supplemental Material). In line with
this, a PET grade 2 was best used for nodules < 12 mm, while
a PET grade of 3 was the optimal cut-point for nodules ≥
12 mm in size.
The location of the nodule did not result in a significant
difference in the diagnostic performance of SUVmax, with an
AUC of 0.82 (95% CI 0.75; 0.89) in the lower lobes versus
0.89 (95% CI 0.85; 0.94) in the mid and upper lobes (p =
0.09).
Comparing the Core read with the site read, the SUVmax
demonstrated good agreement (ICC—0.92 (95%CI 0.91–
0.94)). Bland-Altman plots demonstrated a small but signifi-
cant bias between the site read and core lab read with wide
Fig. 1 STARD flow diagram of
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limits of agreement (mean diff = 0.37 (LOA: − 3.36;4.11,
paired t test: p < 0.001))—see Supplemental Material.
Despite this, when considering a threshold of SUVmax> 2.5
as being malignant, there was excellent agreement between
the site read and core lab read (Kappa (unweighted): 0.93,
p < 0.001). The accuracy of SUVmaxwas the same using both
the site and core read (Core AUC 0.87 (95% CI 0.83; 0.91),
Site AUC 0.86 (95% CI 0.83; 0.90), p = 0.57). As the
SUVmax limits of agreement were wider than expected, we
further reviewed the steps in the scanning and analysis.
Several sites were identified to be using point spread function
reconstruction algorithms which can result in an increase in
SUVmax of up to 25%. Data submitted to the core lab was all
reconstructed using the standard algorithms, but the reporting
sites would have had access to both and it is therefore feasible
that the values from the point spread function reconstruction
would have been recorded in the study case report form.When
the 108 cases from these sites were excluded, leaving n = 247
in the analysis the mean difference was = − 0.06 (LOA: −
2.29–2.42, paired t test: p = 0.41), producing significantly
improved limits of agreement, and the loss of the bias between
the reads. There was excellent agreement between the sites on
the visual qualitative grading of the PET uptake (Kappa (with
squared weighting): 0.87, p < 0.001). The greatest variation in
scoring occurred around Grade 2 which is ‘uptake equivalent
to the mediastinum’ (Supplemental data). There was fair
agreement in the CT visual grading of the nodules
(Weighted Kappa (with squared weighting): 0.33, p <
0.001), with disagreement between site read and core read
most pronounced for Grade 2 lesions (Supplemental data).
Despite this, there was good overall agreement on the pres-
ence of malignancy on the combined PET/CT grading (Kappa
(unweighted): 0.70, p < 0.001). There was also no significant
difference in the accuracy of the core read versus the site read
for either the PET grading (Core: AUC 0.84 (95%CI 0.80;
0.88), Site AUC 0.84 (95% CI 0.80; 0.89), p = 0.92) or the
PET/CT grading (Core: AUC 0.81 (95%CI 0.77; 0.85), Site
AUC 0.82 (95% CI 0.78; 0.86), p = 0.70).
Discussion
This analysis has shown that in a multicentre multivendor
environment, SUVmax is highly accurate for the characterisa-
tion of nodules, that this is more reproducible between
readers, and that normalising this to blood pool or tissue up-
take does not improve accuracy. We have found that accuracy
remains high in small pulmonary nodules < 12 mm, although
diagnostic thresholds need adapting to maintain accuracy both
by visual grading and SUVmax.
Single-centre studies have reported on the diagnostic accu-
racy of PET/CT in the diagnosis of solitary pulmonary nod-
ules. A meta-analysis of 21 such studies found the sensitivity
of PET/CT to be 89% (95%CI 87 to 91%)with a specificity of
70% (95% CI 66 to 73%). All reported studies in this meta-
analysis used SUVmax for determination of malignancy.
However, owing to a lack of standardisation across imaging
Table 1 Baseline participant demographics, and recruitment CT
characteristics
Characteristic Study population (n = 355)
Age, years 67.9 ± 9.0














Prior malignancy 46 (13%)
Recruitment CT characteristics
Nodule location
Right upper lobe 102 (29%)
Right middle lobe 23 (6%)
Right lower lob 74 (21%)
Left upper lobe 80 (23%)
Lingula 15 (4%)
Left lower lobe 61 (17%)





Histology (malignant, n = 209)
Non Small cell lung cancer 147
Adenocarcinoma 112
Squamous cell carcinoma 31
Large cell undifferentiated 2
Not otherwise specified 2
Carcinoid tumour 11
Small cell lung cancer 4
Radiological diagnosis only/SABR 42
Other 5
COPD, chronic obstructive pulmonary disease; CT, computed tomogra-
phy; PMH, past medical history; SABR, sterotactic ablative radiotherapy;
TB, tuberculosis
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centres, an estimated 15–20% variability in SUVmax mea-
surements has been reported [18]. As a result, the British
Thoracic Society recommend an ordinal visual grading scale















































































































CT, computed tomography; PET, positron emission tomography; SURBLOOD, standardised uptake ratio of nodule compared to mediastinal blood pool
uptake; SURLIVER, standardised uptake ratio of nodule compared to liver uptake; SUVmax, standardised uptake value
* PET/CT =met one of the following: grade 4 on either PET or CT; Grade 3 on PET and ≥Grade 2 on CT; ≥Grade 2 on PET and grade 3 on CT
Table 2 PET/CT findings of the nodules in the total cohort, and in those
with a final diagnosis of malignant and benign
Characteristic Benign (n = 146) Malignant (n = 209) P value
Size, mm 12.4 ± 4.5 15.7 ± 5.9 < 0.001
CT grade < 0.001
0 5 (3%) 2 (1%)
1 5 (3%) 1 (0.5%)
2 85 (58%) 48 (23%)
3 51 (35%) 157 (75%)
4 0 (0%) 1 (0.5%)
PET grade < 0.001
0 40 (27%) 5 (2%)
1 64 (45%) 22 (11%)
2 18 (12%) 20 (10%)
3 24 (16%) 157 (75%)
4 0 (0%) 5 (2%)
SUVmax 1.76 ± 1.42 6.39 ± 5.89 < 0.001
SURBLOOD 1.05 ± 0.89 3.60 ± 2.90 < 0.001
SURLIVER 0.75 ± 0.65 2.54 ± 2.12 < 0.001
CT, computed tomography; PET, positron emission tomography;
SURBLOOD, standardised uptake ratio of nodule compared to mediastinal
blood pool uptake; SURLIVER, standardised uptake ratio of nodule com-
pared to liver uptake; SUVmax, standardised uptake value
Fig. 2 Receiver operator characteristic curve for the diagnosis of
malignancy by SUVmax, SURBLOOD, SURLIVER and PET grade
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for the diagnosis of SPNs, referencing the uptake to the me-
diastinal blood pool [19]. A single retrospective
multicentre study performed by Evangelista et al. found that
this visual grading of nodules produced a similar diagnostic
accuracy to that of the meta-analysis with a sensitivity of
85.6% (95% CI: 80.4–90.7%), and specificity of 85.7%
(95% CI: 80.5–90.9%) [14]. In the current study, we found a
lower sensitivity (77.3% (71.0 to 82.8%)) with similar speci-
ficity (82.4% (75.3 to 88.2%)) using a visual ordinal grading
system. This likely reflects several factors. The current study
was prospectively designed and performed, with a high reten-
tion rate with only 6% of patients lost to follow-up compared
with 29% in the study by Evangelista et al. There was also a
high rate of small nodules in our study with 37% of the nod-
ules under 12 mm in maximum diameter.
Despite the overall small size of the pulmonary nodules, we
found a good diagnostic accuracy of PET/CT, with this robust
to nodule size. While the overall accuracy was unaffected by
nodule size, we did however observe a size-dependent effect
on nodule uptake, with the magnitude of this effect greater in
malignant than benign nodules, consistent with previous stud-
ies [20]. As a result of this size-uptake effect, PET/CT speci-
ficity increased, and sensitivity fell with falling nodule size.
This could however be counterbalanced by altering the thresh-
olds for diagnosis of malignancy. Our current results suggest
that, as opposed to using a single cut-point for the diagnosis of
pulmonary nodules, that small nodules (< 12 mm) should be
considered as malignant if the uptake is equal to the medias-
tinum on visual inspection, or with an SUVmax ≥ 1.75, while
for larger nodules (> 16 mm), the threshold should be in-
creased to an SUVmax ≥ 3.6. This is most likely in part due
to partial volume effect. Partial volume correction techniques
have been suggested to correct for this; however, a recent
meta-analysis found no significant benefits of this with sensi-
tivity gains being more than offset by specificity losses [21].
In comparison, altering diagnostic thresholds by size appears
to have salutatory effects on accuracy while also being a tool
available to all PET reporters globally, irrespective of hard-
ware or software.
We did not observe a significant impact of nodule location
on the accuracy of SUVmax. This is in contradistinction to
that of previous studies showing a significantly improved ac-
curacy using respiratory gating [22]. This may reflect the fact
that lower lobe nodules include both nodules near the dia-
phragm where benefits may be maximal as well as nodules
in the apical segments where motion will be minimal. Further
work is warranted to better understand where maximal benefit
may be gained from respiratory gating.
Semi-quantitative analysis of nodules using SUVmax was
remarkably robust in the current study. It produced a high
diagnostic accuracy and was much more reproducible be-
tween readers across multiple sites than was visual ordinal
grading. As the study was performed at 16 sites on 25 different
scanners covering a range of both models and manufactures,
Table 4 Comparison of area under the receiver operator characteristic curves of SUVmax, SURBLOOD and PET grade by nodule size








< 12 mm (n = 133) 0.84 (0.77; 0.91) 1.75 0.84 (0.76; 0.91) 0.83 0.83 (0.76; 0.90) ≥Grade 2
12–16 mm (n = 122) 0.84 (0.77; 0.91) 2.55 0.83 (0.76; 0.91) 1.76 0.79 (0.71; 0.87) ≥Grade 3
> 16 mm (n = 99) 0.89 (0.82; 0.97) 3.6 0.88 (0.80; 0.97) 2.41 0.83 (0.73; 0.93) ≥Grade 3
CT, computed tomography; PET, positron emission tomography; SURBLOOD, standardised uptake ratio of nodule compared to mediastinal blood pool
uptake; SURLIVER, standardised uptake ratio of nodule compared to liver uptake; SUVmax, standardised uptake value
* p > 0.1 for all inter-tertile comparison of AUCs
Fig. 3 Box and whisker plot of SUVmax by nodule size tertile and
malignancy status. B = Benign, M =Malignant. Thick central band =
median; upper and lower bound of box = 75th and 25th centiles
respectively, whiskers reflecting upper and lower limits, with dots
reflecting outliers
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this is an unexpected but important finding. With prior work
suggesting inter-scanner variability of absolute SUVmax,
there should have been significant noise around the threshold
for malignancy. Moreover, normalising this to other tissue
uptake should have improved this. Previous work has demon-
strated that normalising SUVmax to blood pool or liver uptake
to have a high diagnostic accuracy in detection of malignancy
in SPNs with AUCs of 0.90 for both liver and blood uptake
ratios [14]. We observed a similar high diagnostic accuracy in
the current study using this approach, but contrary to expec-
tations, we did not find any ancillary benefit over the use of
SUVmax in isolation.
Despite the higher overall accuracy of SUVmax over visual
ordinal grading, when using single cut-points such as per-
formed in clinical practice, PET grading was as accurate as
SUVmax both in pre-specified and exploratory analysis.
Combining the PET grading with the CT grading produced
the highest accuracy of all the pre-specified techniques, and
equalled those of the exploratory cut points. Given that the
latter may be subject to over-fitting to the current data, this
suggests that combined PET/CT scoring is the most robust
and accurate technique for the analysis of SPNs. This is in
agreement with previous studies showing that, while the in-
cremental benefit is small, CT appearances contribute to nod-
ule categorisation in a useful manner [15, 16]. A critical chal-
lenge of this combined scoring however is that CT grading
appears to be particularly prone to high observer variability,
which impacted the diagnosis of malignancy in a large num-
ber of cases. This is consistent with previous work showing
substantially higher agreement for PET than for CT grading
[23]. This variability may have been potentially exacerbated
in the current study as the original CT was blinded to the core
lab, but not to the site readers. Thus, subtle spiculation, lobu-
lation or heterogeneity of attenuation not evident on the low
dose attenuation correction CT may in fact have been deter-
mined by the standard CT scan causing this marked upgrade
in scoring. However, the equivalent accuracy using core read
PET/CT grade and site read PET/CT grade would suggest that
any bias introduced by this was small. Lung-RADS, which is
a standardised scoring system for nodule assessment in lung
cancer screening studies, may be a more reproducible CT
scoring system due to its well-defined characteristics in each
category [24]. Future studies are warranted to determine if
incorporating this within PET/CT scoring further improves
accuracy or reproducibility.
Despite the high accuracy and reproducibility of SUVmax,
there were significant variations with limits of agreement of −
3.4 to 4.1. This persisted even after removing cases that may
have beenmeasured using a different reconstruction algorithm
at the reporting and Core lab sites. This degree of variability is
in contra-distinction to previous reports where the limits of
agreement are typically ± 0.5–0.8 [25, 26]. However, these
results were for readers all within a single centre using a single
scanner and single post-processing software. In a study by
Marom et al. [27] in which 4 readers read 20 scans, they found
excellent inter-reader agreement. However, the measures of
the 4 readers differed substantially from that documented in
the clinical report, with SUV measurements differing by ≥
25% in 45% of the tumours measured [27].
It is important to note that all centres in the current study
underwent central accreditation, quality assurance and adjust-
ment of protocols as necessary to ensure consistent and com-
parable uptake values by the UK PET Core Lab [13]. The
necessity of such work in ensuring applicability of absolute
quantitative cut-offs is well appreciated, and similar efforts are
underway to improve this globally such as by the EANM/
EARL initiative [28, 29].
There are several limitations to the current study. The sam-
ple sizes in the nodule size subgroups were relatively small,
albeit larger than the majority of existing PET/CT diag-
nostic accuracy studies. As a result, the confidence in-
tervals around the diagnostic accuracy estimates were
larger than in the main study population itself. The pro-
posed sized-based uptake thresholds, particularly for
smaller nodules, will require further validation in future
studies. The current study had a low rate of diagnosis
of infectious diseases as the underlying aetiology of the
nodules; thus, the accuracy and thresholds may not be
translatable to environments where such conditions are
more endemic. Finally, the proposed thresholds only
apply to nodule analysis using standard image recon-
structions and will require further work to translate into
other reconstruction techniques such as point spread
function.
In conclusion, we found that in a multicentre multivendor
trial, SUVmax was the most accurate and reproducible tech-
nique for the diagnosis of solitary pulmonary nodules, and that
diagnostic thresholds should be altered according to nodule
size.
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